Calcitonin Salmon Osteoporosis Treatment Discouraged by FDA Panel

Posted on

A Food and Drug Administration advisory panel has come to the conclusion that the risks of calcitonin salmon when used as an osteoporosis treatment in women who have gone through menopause outweigh the benefits, and thus the substance should no longer be marketed for that treatment.  The calcitonin salmon is meant to limit the risk of a patient’s bones suffering from thinning, but the panel believed that the threat of cancer would be too greatly heightened to justify the treatment.  The matter was decided by a 12-9 margin.  However, the panel decided nearly unanimously that the development of new products in that field should be required to distinctly demonstrate that they limit a patient’s potential exposure to a bone fracture.  The FDA has grown concerned that the calcitonin salmon treatment does not aid fracture prevention.

For more information, click here.